Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9Y2Y1
UPID:
RPC10_HUMAN
Alternative names:
DNA-directed RNA polymerase III subunit K; RNA polymerase III 12.5 kDa subunit; RNA polymerase III subunit C11
Alternative UPACC:
Q9Y2Y1; Q1W6H4; Q96S35
Background:
DNA-directed RNA polymerase III subunit RPC10, also known as the 12.5 kDa subunit, plays a crucial role in transcribing DNA into RNA, focusing on small RNAs like 5S rRNA and tRNAs. It is pivotal in the innate immune response, sensing intracellular bacteria and DNA viruses, and initiating defense mechanisms.
Therapeutic significance:
Linked to Leukodystrophy, hypomyelinating, 21, a neurodegenerative disorder, understanding the role of DNA-directed RNA polymerase III subunit RPC10 could open doors to potential therapeutic strategies.